Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria

(2015) David Tenero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Cytochrome P450 2D Metabolism Alters Tafenoquine Pharmacokinetics

(2015) Chau Vuong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics

(2015) Brittney M. J. Potter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea

(2014) R Joan H Ingram et al.   MALARIA JOURNAL

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds

(2014) Sean R Marcsisin et al.   MALARIA JOURNAL

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

(2013) Alejandro Llanos-Cuentas et al.   LANCET

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6

(2013) Brandon S Pybus et al.   MALARIA JOURNAL

Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria

(2013) Jason W. Bennett et al.   NEW ENGLAND JOURNAL OF MEDICINE

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

(2012) Brandon S Pybus et al.   MALARIA JOURNAL

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

(2008) M C Rebsamen et al.   PHARMACOGENOMICS JOURNAL